10-Q: Verastem Q3 2025: AVMAPKI Launch Drives Revenue, Losses Mount

Verastem, Inc. reports increased revenue from its newly approved cancer drug AVMAPKI FAKZYNJA CO-PACK, but also a significant rise in net loss and ongoing 'going concern' doubts.

Summary

• Net product revenue for the nine months ended September 30, 2025, was $13.4 million, driven by the commercial launch of AVMAPKI FAKZYNJA CO-PACK in May 2025.
• The company's net loss for the nine months ended September 30, 2025, significantly increased to $176.6 million, up from $66.1 million in the prior year.
• Research and development expenses rose by 37% to $82.9 million, primarily due to advancing the RAMP 301 trial and the VS-7375 program.
• Selling, general and administrative expenses surged by 73% to $56.7 million, largely attributed to the commercial launch of AVMAPKI FAKZYNJA CO-PACK.
• Cash, cash equivalents, and investments stood at $137.7 million as of September 30, 2025.
• The company raised $100.1 million from common stock and pre-funded warrants, and $75.0 million from a Note Purchase Agreement during the nine-month period.
• Enrollment for the RAMP 301 confirmatory Phase 3 trial for LGSOC was completed early in September 2025, with an Independent Data Monitoring Committee (IDMC) recommending a modest increase of 29 patients.
• Promising efficacy and safety data were reported for VS-7375 (KRAS G12D inhibitor) from GenFleet's Phase 1/2 study in China, with U.S. trials progressing.
• The company faces substantial doubt about its ability to continue as a going concern for the next 12 months due to anticipated operating losses and the need for additional capital.

Sentiment

Score: 4

Explanation: While the FDA approval and promising pipeline data are significant positives, the substantial increase in net loss, high cash burn, and explicit 'going concern' warning indicate significant financial challenges and risks. The capital raises provide temporary relief but highlight the ongoing need for funding.

Positives

• AVMAPKI FAKZYNJA CO-PACK received FDA approval on May 8, 2025, for KRAS mutant recurrent LGSOC, leading to $13.4 million in net product revenue for the nine months ended September 30, 2025.
• AVMAPKI FAKZYNJA CO-PACK has been included in the National Comprehensive Cancer Network (NCCN) LGSOC treatment guidelines.
• Enrollment for the RAMP 301 confirmatory Phase 3 trial for LGSOC was completed a full quarter early in September 2025 for the initial planned 270 patients.
• VS-7375, an oral KRAS G12D inhibitor, showed promising efficacy in GenFleet's China Phase 1/2 study, with an Objective Response Rate (ORR) of 52% and Disease Control Rate (DCR) of 100% in PDAC patients (400/600 mg QD cohorts) and ORR of 68.8% and DCR of 93.8% in NSCLC patients (600 mg QD RP2D).
• The U.S. Phase 1/2a monotherapy dose escalation trial for VS-7375 cleared 400 mg QD and 600 mg QD doses with no dose-limiting toxicities, and 4 out of 5 efficacy-evaluable patients showed tumor reduction.
• The company secured significant financing, including $100.1 million from equity offerings and $75.0 million from a Note Purchase Agreement, bolstering liquidity to $137.7 million in cash, cash equivalents, and investments.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 167% to $176.6 million, compared to $66.1 million in the prior year.
• Operating expenses increased by 52% to $142.0 million, driven by higher R&D and SG&A costs.
• Selling, general and administrative expenses increased by 73% to $56.7 million, primarily due to the commercial launch of AVMAPKI FAKZYNJA CO-PACK.
• Research and development expenses increased by 37% to $82.9 million, reflecting the high costs of advancing clinical trials and pipeline development.
• The company recorded a $1.8 million loss on debt extinguishment due to the early repayment of the Oxford Loan Agreement.
• A significant expense of $38.0 million was recorded for the change in fair value of warrant liability for the nine months ended September 30, 2025.
• The company's accumulated deficit reached $1,132.1 million as of September 30, 2025.
• The Independent Data Monitoring Committee (IDMC) recommended a modest one-time increase in enrollment for the RAMP 301 trial, which will extend the overall enrollment completion timeline to Q1 2026.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to anticipated operating losses and the need for additional capital.
• Continued approval for AVMAPKI FAKZYNJA CO-PACK for KRAS mutant recurrent LGSOC is contingent upon verification of clinical benefit in a confirmatory trial (RAMP 301).
• The company's ability to obtain additional capital or generate sufficient revenue from commercialization activities is uncertain, which could hinder planned preclinical studies, clinical trials, and regulatory approvals.
• Uncertainty regarding potential regulatory developments in the United States, including drug pricing and reimbursement reforms, could adversely affect the business.
• Increased enforcement of direct-to-consumer (DTC) drug advertising requirements by the FDA may impact sales and marketing efforts.
• Market opportunities for AVMAPKI FAKZYNJA CO-PACK are based on internal and third-party estimates which may prove incorrect, and third-party payors may not reimburse.
• The company relies on third-party contract research organizations, manufacturing organizations, and clinical sites, and their failure to perform could impact operations.
• Substantial competition exists, which may result in others developing or commercializing products more successfully, leading to reduced market share or potential.
• Development and commercialization of product candidates may take longer or cost more than planned.
• The company may be unable to attract and retain high-quality personnel.
• There is a risk that collaboration partners (Pfizer, Chugai, Secura, GenFleet) may fail to fully perform under their respective agreements.
• The company may not see a return on investment on payments made pursuant to the collaboration and option agreement with GenFleet.
• Product candidates may experience manufacturing or supply interruptions or failures.

Future Outlook

The company anticipates continued operating losses for the foreseeable future as it executes its strategic plan, including research and development of product candidates and commercial activities. It expects to finance operations through existing cash, future product revenues, potential milestones/royalties from the Secura APA, the Note Purchase Agreement, or other strategic financing opportunities, though these are not deemed probable for going concern assessment. The company plans to engage with the FDA in the first half of 2026 to discuss the development path for VS-7375, including potential registration-directed clinical trials in PDAC and NSCLC.

Management Comments

• We are a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS MAPK pathway-driven cancers.
• We expect to finance our operations with our existing cash, cash equivalents and investments, through potential future milestones and royalties received pursuant to the Secura APA, through the Note Purchase Agreement, through future product revenues or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, offerings of our equity, or the incurrence of debt.
• If we fail to obtain additional capital or generate sufficient revenue from our commercialization activities in the future, we may be unable to complete our planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the FDA or foreign regulatory authorities. Therefore, there is substantial doubt about our ability to continue as a going concern.

Industry Context

Verastem operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting RAS/MAPK pathway-driven cancers. The recent FDA approval of AVMAPKI FAKZYNJA CO-PACK for LGSOC positions the company in a niche oncology market, while its pipeline, particularly VS-7375 for KRAS G12D mutations, addresses a significant unmet need in pancreatic, colorectal, and lung cancers. The industry faces increasing scrutiny over drug pricing and reimbursement, as highlighted by recent U.S. presidential administration initiatives, which could impact commercial success. The reliance on collaborations (Amgen, GenFleet) and third-party manufacturing/CROs is a common industry practice to manage costs and leverage specialized expertise.

Comparison to Industry Standards

• The 83% objective response rate (ORR) at dose level 1 in the RAMP 205 study for metastatic pancreatic adenocarcinoma, with 10 out of 12 patients achieving partial responses, is a strong signal in a notoriously difficult-to-treat cancer, potentially outperforming historical benchmarks for standard gemcitabine/nab-paclitaxel regimens.
• The VS-7375 data from GenFleet's China study, showing an ORR of 52% and DCR of 100% in heavily pre-treated PDAC patients (400/600 mg QD) and an ORR of 68.8% and DCR of 93.8% in NSCLC patients (600 mg QD RP2D), suggests a potentially best-in-class profile for a KRAS G12D inhibitor, especially when compared to the limited efficacy of existing therapies for these mutations.
• The median progression-free survival (PFS) of 5.52 months and 4-month PFS rate of 78.2% for heavily pre-treated PDAC patients with VS-7375 are encouraging, as advanced PDAC typically has very poor prognosis and short PFS with current treatments.
• The company's accelerated approval pathway for AVMAPKI FAKZYNJA CO-PACK is a common regulatory strategy for drugs addressing high unmet needs, but it carries the industry-standard requirement for confirmatory trials (RAMP 301) to secure full approval.

Stakeholder Impact

• **Shareholders:** Face significant dilution from recent equity raises and potential future capital raises. The 'going concern' warning indicates substantial risk to investment value. However, FDA approval and promising pipeline data offer potential for future growth.
• **Patients:** Benefit from the FDA approval of AVMAPKI FAKZYNJA CO-PACK for LGSOC and the ongoing development of pipeline candidates like VS-7375 for difficult-to-treat cancers.
• **Employees:** The company's continued operations and pipeline advancement provide job security, but the 'going concern' risk could create uncertainty.
• **Creditors (Note Purchasers):** The Note Purchase Agreement is secured by substantially all of the company's assets, including intellectual property related to key products, providing some protection, but the overall financial health remains a concern.
• **Collaboration Partners (Amgen, GenFleet, Pfizer, Chugai, Secura):** Their agreements are tied to the company's success and performance, with potential for milestone payments and royalties. The company's financial stability and clinical progress directly impact these partnerships.

Next Steps

• Complete enrollment of the IDMC-recommended 29 additional patients for the RAMP 301 trial by the first quarter of 2026.
• Present an interim update of safety and efficacy from both the doublet and triplet data in the RAMP 203 study in the fourth quarter of 2025.
• Report an update on the safety and efficacy of the RAMP 205 expansion cohort in the first half of 2026.
• Report an interim safety and efficacy update on the U.S. Phase 1/2a trial of VS-7375 in the first half of 2026.
• Select the recommended Phase 2 dose (RP2D) and initiate monotherapy expansion cohorts for VS-7375 in advanced PDAC, NSCLC, and other solid tumors in the first half of 2026.
• Initiate dose escalation cohorts for VS-7375 in combination with chemotherapy for PDAC, and chemotherapy plus anti-PD-1 for NSCLC in the fourth quarter of 2025.
• Select the RP2D and initiate combination expansion cohorts for VS-7375 in CRC, PDAC, and NSCLC in the first half of 2026.
• Engage with the FDA in the first half of 2026 to discuss the development path for VS-7375, including potential registration-directed clinical trials in PDAC and NSCLC.
• Additional data, including efficacy (response rates) and updated safety, for the RAMP 201J trial will be available on November 5, 2025.

Key Dates

Recommendation

The company has achieved a significant milestone with the FDA approval and commercial launch of AVMAPKI FAKZYNJA CO-PACK, establishing its first product revenue stream. The pipeline, particularly VS-7375, shows promising early clinical data in challenging oncology indications. However, these positives are overshadowed by a substantial increase in net loss, a high cash burn rate, and an explicit 'going concern' warning, indicating significant financial instability. While recent capital raises provide some liquidity, the company's long-term viability hinges on continued successful commercialization and further financing. A 'hold' recommendation is appropriate as the stock presents both high-risk and high-reward potential, requiring investors to monitor financial performance and clinical milestones closely before making further commitments.

Keywords

Verastem, VSTM, AVMAPKI FAKZYNJA CO-PACK, avutometinib, defactinib, KRAS mutant, LGSOC, low grade serous ovarian cancer, RAS MAPK pathway, oncology, biopharmaceutical, clinical trials, RAMP 301, VS-7375, KRAS G12D, pancreatic cancer, NSCLC, non-small cell lung cancer, FDA approval, SEC filing, 10-Q, financial results, going concern, drug development